Fit to beat diabetes: mendelian randomization study confirms the power of exercise

A new biotech start­up launched Wednes­day to ad­vance a “Goldilocks” ther­a­peu­tic modal­i­ty that could turn some of the in­dus­try’s most lu­cra­tive drugs in­to pills. Berke­ley,

Foghorn Ther­a­peu­tics said Wednes­day morn­ing that it was stop­ping fur­ther work on an ex­per­i­men­tal drug for a rare ad­vanced eye can­cer that has spread to